Pemvidutide in alcohol-associated liver disease (ALD) Recent Highlights: In May 2026, the company announced that Pemvidutide demonstrated significant metabolic improvements in patients with MASH in new 48week IMPACT Phase 2b data
J2992, JA2501, JA2505 ADCP Reporter Bioassay (THP-1) Measure the potency and stability of antibodies and other biologics with Fc domains that bind and activate FcRs
Our approach is holistic, addressing all aspects of health, including mindset, exercise, sleep, hormones, nutrition, and gut health
Research Applications Published Research Peer-reviewed studies from PubMed
Sequel of chronic use of laxative of the anthraquinone group, which includes cascara sagrada, aloe, rhubarb, senna and fragula
The honest US status: TA1 is not an FDA-approved drug in the United States